Beam Therapeutics reported a significant miss on both top and bottom lines for the third quarter of 2026, primarily due to a sharp decline in collaboration revenue. Despite the financial miss, the company maintained its clinical timelines and strong liquidity position, with sufficient capital to fund operations through several potential commercial launches.
Key Highlights
- License and collaboration revenue plummeted to $0.3 million from $9.7 million in the prior-year period, missing the $9.96 million analyst estimate.
- Net loss widened to $134.4 million, or $1.28 per share, compared to $112.6 million, or $1.10 per share, missing the consensus estimate of a $1.17 loss.
- Management reaffirmed the timeline for the risto-cel BLA submission in sickle cell disease as early as year-end 2026.
- Total liquidity of $1.0 billion in cash and marketable securities, plus a $200 million debt facility, is projected to support operations into mid-2029.